Pathophysiology and Management of Portal Hypertension

Portal hypertension arises when the pressure gradient between the portal vein and hepatic veins exceeds normal limits, most commonly as a consequence of cirrhosis and extensive fibrotic remodelling. Progressive deposition of extracellular matrix narrows sinusoidal lumina, while dysregulation of endothelial nitric-oxide synthase and enhanced Rho-kinase activity promote intrahepatic vasoconstriction. Simultaneously, splanchnic vasodilatation and neoangiogenesis drive a hyperdynamic circulatory state, exacerbating transhepatic flow and predisposing to variceal bleeding, ascites and hepatic encephalopathy. Traditional management focuses on prevention of complications by reducing portal pressure through non-selective β-adrenoceptor blockers, endoscopic band ligation and use of diuretics to control ascites. Interventional approaches such as transjugular intrahepatic portosystemic shunt (TIPS) offer decompression when medical therapy fails, albeit with risks of hepatic encephalopathy. Emerging strategies aim to restore sinusoidal function by modulating mechanobiological pathways, targeting profibrotic signalling cascades and improving endothelial responsiveness. Integration of pharmacological, endoscopic and interventional measures—guided by individual risk stratification and aetiological control—remains central to optimising outcomes in portal hypertension.

Research from Nature Portfolio

Recent studies have demonstrated promising advances in targeted vasomodulators and antifibrotic agents. In preclinical models, selective stimulation of soluble guanylate cyclase has been shown to restore nitric-oxide signalling within the cirrhotic liver, decreasing intrahepatic resistance and regressing fibrosis without compromising systemic haemodynamics. Another approach uses receptor-guided delivery of Rho-kinase inhibitors to hepatic stellate cells, effectively lowering portal pressure, reducing fibrogenesis and preserving renal perfusion; this strategy underscores the potential for cell-specific small-molecule therapy to reshape clinical management.

Pathophysiology and Management of Portal Hypertension publication trend

The graph below shows the total number of articles in pathophysiology and management of portal hypertension across all publications each year (not limited to Nature Index journals).

Technical terms

Portal hypertension: A sustained elevation of pressure within the portal venous system, typically above 10 mm Hg, resulting from increased intrahepatic resistance and hyperdynamic splanchnic circulation.

Soluble guanylate cyclase (sGC): An enzyme activated by nitric oxide that synthesises cyclic guanosine monophosphate (cGMP), leading to vasodilation and reduced vascular resistance.

Rho-kinase (ROCK): A serine/threonine kinase downstream of the RhoA GTPase, which regulates cytoskeletal tone, cell contraction and extracellular matrix deposition.

Transjugular intrahepatic portosystemic shunt (TIPS): An interventional radiological procedure that creates a channel between the portal and hepatic veins to decompress the portal system and alleviate complications.

References

1. Mechanobiology of portal hypertension. JHEP Reports (2023).
2. The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. Scientific Reports (2018).
3. Nuclear deformation mediates liver cell mechanosensing in cirrhosis. JHEP Reports (2020).
4. Managing portal hypertension in patients with liver cirrhosis. F1000Research (2018).
5. Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats. Scientific Reports (2019).